Stocktoria
PLUS THERAPEUTICS, INC. PSTV
PLUS THERAPEUTICS, INC. (PSTV) earns a Piotroski F-score of 3/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $5.2M at a -429.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| PSTV | PLUS THERAPEUTICS, INC. | 3/9 | — | — | — |
| LUCD | Lucid Diagnostics Inc. | 3/9 | — | — | — |
| TNON | Tenon Medical, Inc. | 4/9 | — | — | — |
| IVF | INVO Fertility, Inc. | 4/9 | -19.01 | — | — |
| AURX | Nuo Therapeutics, Inc. | 3/9 | — | — | — |
| INBS | INTELLIGENT BIO SOLUTIONS INC. | 2/9 | — | — | — |
| OSRH | OSR Health, Inc. | — | 1.04 | — | — |
About PLUS THERAPEUTICS, INC.
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests comprising the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Houston, Texas.
FAQ
Is PSTV financially healthy?
PLUS THERAPEUTICS, INC.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak).
Does PSTV pay a dividend?
No, PLUS THERAPEUTICS, INC. does not currently pay a dividend.
How profitable is PSTV?
In FY2025, PLUS THERAPEUTICS, INC. had a net margin of -429.4% and a return on equity of -560.2%.
What is the analyst price target for PSTV?
The average Wall-Street price target for PLUS THERAPEUTICS, INC. is $36.00, from 4 analysts.
Is PSTV a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on PLUS THERAPEUTICS, INC.: a Piotroski F-score of 3/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.